"ARVO 2023: Life Biosciences and Iveric Bio showcase promising vision restoration data in nonhuman primates and clinical trials"

TL;DR Summary
Life Biosciences presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) conference demonstrating the ability to restore visual function in nonhuman primates (NHP) after delivery of a novel gene therapy candidate using a partial epigenetic reprogramming approach. The therapy significantly restored visual function in an NHP model of non-arteritic anterior ischemic optic neuropathy (NAION), a disorder similar to a stroke of the eye that is characterized by painless yet sudden loss of vision. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity.
Topics:business#epigenetic-reprogramming#gene-therapy#health#life-biosciences#nonhuman-primates#visual-function
- Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates GlobeNewswire
- Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting Business Wire
- ARVO 2023: Life Biosciences presents groundbreaking data at ARVO demonstrating Restoration of Visual Function in Nonhuman Primates Ophthalmology Times
- ARVO LIVE: Analysis of vision loss from GATHER clinical program Ophthalmology Times
- ARVO LIVE: Lexitas modified National Eye Institute scale Ophthalmology Times
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
91%
1,004 → 94 words
Want the full story? Read the original article
Read on GlobeNewswire